The Economic Times of India has reported on a study of the Indian biosimilars market conducted by the Jawaharlal Nehru Institute of Advanced Studies (JNIAS).

The study reports that the Indian biosimilars industry was close to $300 million in 2015, with domestic sales accounting for $250 million growing at a compound annual growth rate of 14 per cent, and exports accounting for close to $51 million.  The study concludes that the recent addition of a new regulatory policy in India, which may refer to India’s Revised Guidelines on Similar Biologics, and the increased affordability offered by biosimilars, paves the way for the Indian domestic biosimilar market to grow at an accelerated pace and to reach a $40 billion target by 2030 (approximately 16% of the study’s projected global market of $240 billion).

For more biosimilar news, stay tuned to Big Molecule Watch.